Carmen Delgado Pecellín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen Delgado Pecellín has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- María Bueno
Dpto. de Pediatría, Hospital Universitario Virgen del Rocío, 28034 Sevilla, Spain
2 shared publications - Antonia Ribes
Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
1 shared publication - Araceli Ferrari-Cortes
Unidad de Neonatología, Hospital Universitario Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
1 shared publication - Beatriz de Felipe
Unidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain
1 shared publication - Berta Sánchez
Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
1 shared publication - Carlos Jimenez Contreras
Asociación Española de Déficits Inmunitarios Primarios (AEDIP), 28050 Madrid, Spain
1 shared publication
Latest Publications
- 5 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 249, 108477
Not everything salty is cystic fibrosis
- 5 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 249, 108477
Not everything salty is cystic fibrosis
- Open Access
- 7 October 2017
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 3 (4) , 27
Newborn Screening for Primary T- and B-Cell Immune Deficiencies—A Prospective Study in Andalucía
Background: Quantification of T-cell-receptor-excision circles (TRECs) and kappa-deleting-recombination-excision circles (KRECs) from dried blood spots (DBS) allows detection of neonates with severe T-cell and/or B-cell lymphopenia that are potentially affected by severe combined immunodeficiency (SCID), as well as X-linked agammaglobulinemia (XLA). Methods: Determination of TRECs and KRECs using a triplex RT-PCR (TRECS-KRECS-β-actin) assay from prospectively collected DBS between February 2014 and December 2016 in three hospitals in Seville, Spain. Cut-off levels were TRECs < 6/punch, KRECs < 4/punch and b-actin > 700/punch. Internal (SCID, XLA, ataxia telangiectasia) and external controls (CDC) were included. Results: A total of 8943 DBS samples obtained from 8814 neonates were analysed. Re-punching was necessary in 124 samples (1.4%) due to insufficient β-actin values (<700 copies/punch). Preterm neonates (GA < 37 weeks) and neonates with a BW < 2500 g showed significantly lower TRECs and KRECs levels (p < 0.001). Due to repeated pathological results, ten neonates were re-sampled (0.11%), of which five neonates (0.055%) confirmed the pathological results: one case was a fatal chromosomopathy (TRECs 1/KRECs 4); two were extreme premature newborns (TRECs 0/KRECs 0 and TRECs 1/KRECs 20 copies/punch); and 2 neonates were born to mothers receiving azathioprine during pregnancy (TRECs 92/KRECs 1 and TRECs 154/KRECs 3 copies/punch). All controls were correctly identified. Conclusions: Severe T- and B-cell lymphopenias were correctly identified by the TRECS-KRECS-β-actin assay. Prematurity and low BW are associated with lower TREC and KREC levels. Extreme prematurity and maternal immune suppressive therapy can cause false positive results of TRECs and KRECs values.
- 7 October 2017
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 3 (4) , 27
Open AccessNewborn Screening for Primary T- and B-Cell Immune Deficiencies—A Prospective Study in Andalucía
Background: Quantification of T-cell-receptor-excision circles (TRECs) and kappa-deleting-recombination-excision circles (KRECs) from dried blood spots (DBS) allows detection of neonates with severe T-cell and/or B-cell lymphopenia that are potentially affected by severe combined immunodeficiency (SCID), as well as X-linked agammaglobulinemia (XLA). Methods: Determination of TRECs and KRECs using a triplex RT-PCR (TRECS-KRECS-β-actin) assay from prospectively collected DBS between February 2014 and December 2016 in three hospitals in Seville, Spain. Cut-off levels were TRECs < 6/punch, KRECs < 4/punch and b-actin > 700/punch. Internal (SCID, XLA, ataxia telangiectasia) and external controls (CDC) were included. Results: A total of 8943 DBS samples obtained from 8814 neonates were analysed. Re-punching was necessary in 124 samples (1.4%) due to insufficient β-actin values (<700 copies/punch). Preterm neonates (GA < 37 weeks) and neonates with a BW < 2500 g showed significantly lower TRECs and KRECs levels (p < 0.001). Due to repeated pathological results, ten neonates were re-sampled (0.11%), of which five neonates (0.055%) confirmed the pathological results: one case was a fatal chromosomopathy (TRECs 1/KRECs 4); two were extreme premature newborns (TRECs 0/KRECs 0 and TRECs 1/KRECs 20 copies/punch); and 2 neonates were born to mothers receiving azathioprine during pregnancy (TRECs 92/KRECs 1 and TRECs 154/KRECs 3 copies/punch). All controls were correctly identified. Conclusions: Severe T- and B-cell lymphopenias were correctly identified by the TRECS-KRECS-β-actin assay. Prematurity and low BW are associated with lower TREC and KREC levels. Extreme prematurity and maternal immune suppressive therapy can cause false positive results of TRECs and KRECs values.
- Open Access
- 1 January 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 102
Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common inherited defect in the mitochondrial fatty acid oxidation pathway, resulting in significant morbidity and mortality in undiagnosed patients.
- 1 January 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 102
Open AccessNewborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common inherited defect in the mitochondrial fatty acid oxidation pathway, resulting in significant morbidity and mortality in undiagnosed patients.
- 10 September 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (S3) , 363-371
Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density
Background: Patients with phenylketonuria (PKU) undergo a restrictive vegan‐like diet, with almost total absence of n‐3 fatty acids, which have been proposed as potential contributors to bone formation in the healthy population. The PKU diet might lead these patients to bone mass loss and, consequently, to the development of osteopenia/osteoporosis. Therefore, we proposed to analyze their plasma fatty acid profile status and its relationship with bone health.Methods: We recruited 47 PKU patients for this cross‐sectional study and divided the cohort into three age groups (6–10 years, 11–18 years, 19–42 years). We measured their plasma fatty acid profile and bone mineral density (BMD) (both at the femoral neck and the lumbar spine). Seventy‐seven healthy controls also participated as reference values of plasma fatty acids.Results: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and total n‐3 fatty acids were significantly diminished in PKU patients compared with healthy controls. DHA, EPA, and total n‐3 fatty acids were also positively associated with bone mineral density (r = 0.83, p = 0.010; r = 0.57, p = 0.006; r = 0.73, p = 0.040, respectively). There was no association between phenylalanine (Phe), Index of Dietary Control (IDC), calcium, 25‐hydroxivitamin D concentrations, daily calcium intake, and BMD.Conclusion: Our results suggest a possible influence of essential fatty acids over BMD in PKU patients. The lack of essential n‐3 fatty acids intake in the PKU diet might affect bone mineralization. Further clinical trials are needed to confirm the effect of the n‐3 essential fatty acids on bone accrual in a cohort of PKU patients.
- 10 September 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (S3) , 363-371
Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density
Background: Patients with phenylketonuria (PKU) undergo a restrictive vegan‐like diet, with almost total absence of n‐3 fatty acids, which have been proposed as potential contributors to bone formation in the healthy population. The PKU diet might lead these patients to bone mass loss and, consequently, to the development of osteopenia/osteoporosis. Therefore, we proposed to analyze their plasma fatty acid profile status and its relationship with bone health.Methods: We recruited 47 PKU patients for this cross‐sectional study and divided the cohort into three age groups (6–10 years, 11–18 years, 19–42 years). We measured their plasma fatty acid profile and bone mineral density (BMD) (both at the femoral neck and the lumbar spine). Seventy‐seven healthy controls also participated as reference values of plasma fatty acids.Results: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and total n‐3 fatty acids were significantly diminished in PKU patients compared with healthy controls. DHA, EPA, and total n‐3 fatty acids were also positively associated with bone mineral density (r = 0.83, p = 0.010; r = 0.57, p = 0.006; r = 0.73, p = 0.040, respectively). There was no association between phenylalanine (Phe), Index of Dietary Control (IDC), calcium, 25‐hydroxivitamin D concentrations, daily calcium intake, and BMD.Conclusion: Our results suggest a possible influence of essential fatty acids over BMD in PKU patients. The lack of essential n‐3 fatty acids intake in the PKU diet might affect bone mineralization. Further clinical trials are needed to confirm the effect of the n‐3 essential fatty acids on bone accrual in a cohort of PKU patients.